RTP Mobile Logo
Select Publications

Barroso-Sousa R et al. Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. Oncologist 2021;[Online ahead of print]. Abstract

Barroso-Sousa R, Tolaney SM. Clinical development of new antibody-drug conjugates in breast cancer: To infinity and beyond. BioDrugs 2021;35(2):159-74. Abstract

Brown JC et al. The effects of a clinic-based weight loss program on health-related quality of life and weight maintenance in cancer survivors: A randomized controlled trial. Psychooncology 2021;[Online ahead of print]. Abstract

Exman P, Tolaney SM. HER2-positive metastatic breast cancer: A comprehensive review.Clin Adv Hematol Oncol 2021;19(1):40-50. Abstract

Jackisch C et al. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treat Rev 2021;99:102229. Abstract

Leone J et al. Tumor subtypes and survival in male breast cancer. Breast Cancer Res Treat 2021;188(3):695-702. Abstract

Leone JP et al. Survival in male breast cancer (MaBC) over the past three decades. ASCO 2021;Abstract 569.

Pernas S, Tolaney SM. Management of early-stage human epidermal growth factor receptor 2-positive breast cancer. JCO Oncol Pract 2021;17(6):320-30. Abstract

Pernas S, Tolaney SM. Targeting HER2 heterogeneity in early-stage breast cancer. Curr Opin Oncol 2020;32(6):545-54. Abstract

Tolaney SM et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial. J Clin Oncol 2021;39(21):2375-85. Abstract

Tolaney SM et al. Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. ESMO 2021;Abstract 328TiP.

Weis LN et al. Tissue-agnostic drug approvals: How does this apply to patients with breast cancer? NPJ Breast Cancer 2021;7(1):120. Abstract